Published in Ann Rheum Dis on June 01, 2005
Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res (2010) 1.33
Retroperitoneal fibrosis in 27 Korean patients: single center experience. J Korean Med Sci (2011) 0.95
Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair (2014) 0.89
Percutaneous treatment of a aorto-caval fistula in a old high risk patient. BMC Surg (2012) 0.87
Management of idiopathic retroperitoneal fibrosis from the urologist's perspective. Ther Adv Urol (2015) 0.86
An aid to decision-making in therapy of retroperitoneal fibrosis: dynamic enhancement analysis of gadolinium MRI. J Clin Med Res (2013) 0.84
Retroperitoneal fibrosis: retrospective descriptive study on clinical features and management. Res Rep Urol (2016) 0.84
Retroperitoneal fibrosis: a retrospective clinical data analysis of 30 patients in a 10-year period. Chin Med J (Engl) (2015) 0.82
Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J (2016) 0.79
Medical management of retroperitoneal fibrosis. Trans Am Clin Climatol Assoc (2012) 0.77
An unusual case of acute on chronic renal failure following percutaneous coronary intervention. BMJ Case Rep (2009) 0.75
Retroperitoneal fibrosis - the state-of-the-art. Reumatologia (2016) 0.75
Medical Therapy of Fibrostenotic Crohn's Disease. Viszeralmedizin (2015) 0.75
Ureteric obstruction secondary to retroperitoneal fibrosis leading to acute kidney injury. BMJ Case Rep (2013) 0.75
[Scleroderma and fibrosing diseases]. Z Rheumatol (2009) 0.75
Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol (1987) 2.34
Inflammatory aneurysms of the abdominal aorta. Br J Surg (1972) 2.05
The clinical significance of retroperitoneal fibrosis. Surgery (1977) 1.99
Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med (1990) 1.47
Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet (2004) 1.44
Chronic periaortitis and periarteritis. Histopathology (1984) 1.44
Retroperitoneal fibrosis. A true connective tissue disease. Rheum Dis Clin North Am (1996) 1.32
Inflammatory abdominal aortic aneurysms: a case-control study. J Vasc Surg (1996) 1.23
Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med (2004) 1.15
Renal failure due to peri-ureteric fibrosis. Br J Surg (1958) 1.04
The diagnosis and treatment of peri-aortic fibrosis ('inflammatory' aneurysms). Br J Surg (1983) 0.98
Symptoms and diagnosis of retroperitoneal fibrosis. Analysis of 31 cases. Urol Int (1971) 0.96
Inflammatory abdominal aortic aneurysm: A postoperative course of retroperitoneal fibrosis. J Vasc Surg (1999) 0.95
Retroperitoneal fibrosis with antineutrophil cytoplasmic antibodies. J Rheumatol (1996) 0.94
The inflammatory abdominal aortic aneurysm. Prevalence, clinical features and diagnostic evaluation. Neth J Med (1993) 0.91
Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. Lancet (1998) 0.90
CT and MR imaging in the evaluation of retroperitoneal fibrosis. J Comput Assist Tomogr (1989) 0.90
Retroperitoneal fibrosis and systemic lupus erythematosus. Nephrol Dial Transplant (1999) 0.90
Retroperitoneal fibrosis due to Wegener's granulomatosis: a misdiagnosis as tuberculosis. Am J Med (2002) 0.90
Radiologic investigation of abdominal aortic aneurysm disease: comparison of three modalities in staging and the detection of inflammatory change. J Vasc Surg (1993) 0.88
Characterization of inflammatory cells in a patient with chronic periaortitis. Am J Cardiovasc Pathol (1990) 0.87
Retroperitoneal fibrosis treated with tamoxifen. Am Surg (1995) 0.87
ANCA-positive periaortic vasculitis: does it fall within the spectrum of vasculitis? J Intern Med (2002) 0.86
Value of various treatments for retroperitoneal fibrosis. Eur Urol (1981) 0.86
Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis (2001) 0.85
Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. Clin Rheumatol (1995) 0.83
[Systemic fibrosis (generalized form of Ormond's disease). Report of a case which achieved complete remission with cyclophosphamide and corticosteroids]. Schweiz Med Wochenschr (1995) 0.79
[MRI and CT in diagnosis and follow-up of idiopathic (retroperitoneal) fibrosis]. Radiologe (1995) 0.78
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet (2005) 3.97
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol (1999) 2.52
The GroE chaperonin machine is a major modulator of the CIRCE heat shock regulon of Bacillus subtilis. EMBO J (1997) 2.50
Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol (2003) 2.20
Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthritis Cartilage (2006) 2.13
Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity (1995) 1.83
Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol (1975) 1.82
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis (2008) 1.81
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis (2003) 1.75
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis (2010) 1.73
The activation of female sex hormones: alpha-Oestradiol and its di-esters. Biochem J (1938) 1.69
Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study. Eur J Nucl Med (1997) 1.66
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology (1990) 1.60
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis (2009) 1.59
Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature. Br J Rheumatol (1998) 1.56
Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) (2000) 1.52
Transient hypogammaglobulinemia of infancy: Five new cases, review of the literature and redefinition. Acta Paediatr Scand (1989) 1.51
Magnetic resonance imaging (MRI) for detection of active sacroiliitis--a prospective study comparing conventional radiography, scintigraphy, and contrast enhanced MRI. J Rheumatol (1996) 1.49
The activation of female sex hormones: Oestrone and its esters. The output of activity and efficiency coefficient. Biochem J (1938) 1.49
Type II collagen-specific human T cell lines established from healthy donors. Eur J Immunol (1990) 1.47
Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings. Eur J Immunol (1996) 1.47
Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol (2011) 1.44
Intravascular coagulation necrosis of the skin associated with cryofibrinogenemia, diabetes mellitus, and cardiolipin autoantibodies. J Am Acad Dermatol (1991) 1.39
Inspiratory stridor and dysphagia in two newborn infants caused by ectopic thymus tissue. Eur J Pediatr (2008) 1.39
First description of three patients with multifocal lymphangiomatosis and protein-losing enteropathy following palliation of complex congenital heart disease with total cavo-pulmonary connection. Pediatr Cardiol (2008) 1.39
Posttraumatic reflex sympathetic dystrophy anteceding inverse psoriasis and psoriatic arthritis. J Rheumatol (1995) 1.39
A public domain image-analysis program for the single-cell gel-electrophoresis (comet) assay. Mutat Res (2000) 1.35
FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol (2000) 1.33
The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells. J Immunol (2000) 1.32
Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J Immunol (2000) 1.31
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
The DiGeorge syndrome. I. Clinical evaluation and course of partial and complete forms of the syndrome. Eur J Pediatr (1988) 1.27
Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol (2007) 1.26
Overexpression of zinc-finger transcription factor Z-225/Egr-1 in synoviocytes from rheumatoid arthritis patients. J Immunol (1994) 1.23
Failure of potassium siphoning by Müller cells: a new hypothesis of perfluorocarbon liquid-induced retinopathy. Invest Ophthalmol Vis Sci (2000) 1.22
Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat (2006) 1.21
Modular structure of the trigger factor required for high activity in protein folding. J Mol Biol (1997) 1.21
Spontaneous cytotoxicity (SCMC) of normal human lymphocytes against a human melanoma cell line: a phenomenon due to a lymphotoxin-like mediator. J Immunol (1976) 1.20
Slit-lamp-adapted optical coherence tomography of the anterior segment. Graefes Arch Clin Exp Ophthalmol (2000) 1.19
Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis. Scand J Immunol (1978) 1.19
Immunophenotypical alterations in a subset of patients with common variable immunodeficiency (CVID). Clin Exp Immunol (1992) 1.19
3-Alkanoyl-5-hydroxymethyl tetronic acid homologues and resistomycin: new inhibitors of HIV-1 protease. I. Fermentation, isolation and biological activity. J Antibiot (Tokyo) (1994) 1.19
Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol (2005) 1.18
Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity. Cell (1997) 1.18
Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res (2001) 1.17
Effect of shortening the barrel in contact shots from rifles and shotguns. Int J Legal Med (2007) 1.16
Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol (1998) 1.15
Tumour of the spermatic cord: an unusual primary manifestation of an epithelial mesothelioma of the peritoneum with patent processus vaginalis. BJU Int (2000) 1.15
Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum (2005) 1.14
Mycoplasma contamination in human tumor cell lines: effect on interferon induction and susceptibility to natural killing. J Immunol (1981) 1.13
Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis. Rheumatol Int (1995) 1.13
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis (2008) 1.13
Dynamic association of trigger factor with protein substrates. J Mol Biol (2001) 1.11
Hoffa fracture--a radiologic diagnostic approach. J Belge Radiol (1996) 1.10
Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest (1992) 1.10
Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis (2000) 1.08
Corneal optical coherence tomography before and immediately after excimer laser photorefractive keratectomy. Am J Ophthalmol (2000) 1.08
Testing for association in SLE families. Genet Epidemiol (1991) 1.07
Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol (2000) 1.07
The DiGeorge sequence. II. Immunologic findings in partial and complete forms of the disorder. Eur J Pediatr (1989) 1.07
Biased T cell receptor V alpha region repertoire in the synovial fluid of rheumatoid arthritis patients. Eur J Immunol (1991) 1.07
Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat Res (1998) 1.06
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis (2010) 1.05
Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of phospholipase A2. Structural revision of duramycin and cinnamycin. J Antibiot (Tokyo) (1990) 1.05
Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2). Food Chem Toxicol (2005) 1.03
Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol (2007) 1.03
Photoshop-based image analysis of canine articular cartilage after subchondral damage. Arch Orthop Trauma Surg (2004) 1.03
Anastomotic stricture after radical prostatectomy. Incidence, findings and treatment. Eur Urol (1998) 1.03
Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol (2001) 1.03
Human peripheral null lymphocytes. II. Producers of type-1 interferon upon stimulation with tumor cells, Herpes simplex virus and Corynebacterium parvum. Eur J Immunol (1980) 1.02
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol (2007) 1.02
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis (2001) 1.02
Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol (1988) 1.02
Low dose methotrexate therapy for rheumatoid arthritis complicated by pancytopenia and Pneumocystis carinii pneumonia. J Rheumatol (1991) 1.02
MR imaging of the carpal tunnel. Eur J Radiol (1997) 1.02
The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford) (2000) 1.00
Measurement of peripheral B cell subpopulations in common variable immunodeficiency (CVID) using a whole blood method. Clin Exp Immunol (2005) 1.00
Possible role of IL-2 deficiency for hypogammaglobulinaemia in patients with common variable immunodeficiency. Clin Exp Immunol (1992) 1.00
Classification of graft hypertrophy after autologous chondrocyte implantation of full-thickness chondral defects in the knee. Osteoarthritis Cartilage (2007) 1.00
IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. SLE Study Group. Rheumatol Int (1998) 1.00
A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood (1993) 1.00
Tracer test with As(V) under variable redox conditions controlling arsenic transport in the presence of elevated ferrous iron concentrations. J Contam Hydrol (2006) 0.99
Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol Suppl (2000) 0.98
Numerical and functional alterations of lymphocytes in human schistosomiasis. Scand J Immunol (1984) 0.98
Cyclophilin and trigger factor from Bacillus subtilis catalyze in vitro protein folding and are necessary for viability under starvation conditions. Biochemistry (1998) 0.97
["Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab]. Dtsch Med Wochenschr (2001) 0.97
Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int (1988) 0.97
Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. J Med Chem (1991) 0.96
No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology (Oxford) (2002) 0.96
New bioresorbable pin for the reduction of small bony fragments: design, mechanical properties and in vitro degradation. Biomaterials (1996) 0.96
Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis (2012) 0.95